Loading…
Reported covered position: Deputy Legislative Director, Leg Asst, Sen. Cruz; Leg Asst, Sen. DeMint.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Sustainable Cardiopulmonary Rehabilitation Services in the Home Act
Client: RECORA · Firm: WILLIAMS AND JENSEN, PLLC
Provide government affairs services and support for Recora's legislative priorities, including H.R. 1406, the Sustainable Cardiopulmonary Rehabilitation Services in the Home Act.
Sustainable Cardiopulmonary Rehabilitation Services in the Home Act
Client: RECORA · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to Medicare coverage of telehealth and health provider supervision flexibilities. Medicare coverage of virtual and in-home cardiac rehabilitation services, including H.R. 1406--Sustainable Cardiopulmonary Rehabilitation Services in the Home Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BUSINESS ROUNDTABLE via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
H.R.7024--Tax Relief for American Families and Workers Act of 2024. Issues of interest to the broad business community, including corporate tax rate and international tax rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · 4T
Source: Senate LDA
| OWENS & MINOR, INC. |
| 5 |
| 2023–2024 |
| PFIZER | 5 | 2023–2024 |
| PHRMA | 5 | 2023–2024 |
| PLASMA PROTEIN THERAPEUTICS ASSOCIATION | 5 | 2023–2024 |
| RAYNER | 5 | 2023–2024 |
| SANOFI, U.S. | 5 | 2023–2024 |
| SYNEOS HEALTH, INC. | 5 | 2023–2024 |
| WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) | 5 | 2024 |
| ZOETIS | 5 | 2023–2024 |
| ARGENTUM MEDICAL | 4 | 2024 |
| ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) | 4 | 2023–2024 |
| INDIVIOR INC. | 4 | 2023–2024 |
| IRHYTHM TECHNOLOGIES | 4 | 2023–2024 |
| NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES | 4 | 2023–2024 |
| RIVER REGION PSYCHIATRY ASSOCIATES | 4 | 2024 |
| RECORA | 3 | 2024 |
| DR. EMIL KAKKIS | 2 | 2023–2024 |
| RESEARCH SOCIETY ON ALCOHOL (FORMERLY KNOWNS AS RESEARCH SOCIETY ON ALCOHOLISM) | 2 | 2024 |
| BEONE MEDICINES ( FORMERLY KNOWN AS BEIGENE USA, INC.) | 1 | 2023 |
| COLORADO WEST HEALTHCARE SYSTEM, INC. DBA COMMUNITY HOSPITAL | 1 | 2023 |
| EXIGER | 1 | 2024 |
| SOLVD HEALTH | 1 | 2024 |
Sustainable Cardiopulmonary Rehabilitation Services in the Home Act
Client: RECORA · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to Medicare coverage of telehealth and health provider supervision flexibilities. Medicare coverage of virtual and in-home cardiac rehabilitation services, including H.R. 1406--Sustainable Cardiopulmonary Rehabilitation Services in the Home Act.
Sustainable Cardiopulmonary Rehabilitation Services in the Home Act
Client: RECORA · Firm: WILLIAMS AND JENSEN, PLLC
Provide government affairs services and support for Recora's legislative priorities, including H.R. 1406, the Sustainable Cardiopulmonary Rehabilitation Services in the Home Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act. American Relief Act (P.L. 118-158).
FAIR Act
Client: ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) · Firm: WILLIAMS AND JENSEN, PLLC
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage program. Telehealth policies. H.R. 3417.
FAIR Act
Client: ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) · Firm: WILLIAMS AND JENSEN, PLLC
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage program. Telehealth policies. H.R. 3417.
FAIR Act
Client: ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) · Firm: WILLIAMS AND JENSEN, PLLC
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. Policies impacting U.S. address to the Covid-19 pandemic. Telehealth policies. H.R. 3417.
FAIR Act
Client: ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) · Firm: WILLIAMS AND JENSEN, PLLC
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. Policies impacting U.S. address to the Covid-19 pandemic. Telehealth policies. H.R. 3417.
Preparing for All Hazards and Pathogens Reauthorization Act
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421).
Preparing for All Hazards and Pathogens Reauthorization Act
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421).
Preparing for All Hazards and Pathogens Reauthorization Act
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421).
Preparing for All Hazards and Pathogens Reauthorization Act
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421). American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
EMPOWER Act
Client: NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES · Firm: WILLIAMS AND JENSEN, PLLC
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Proposals to extend coverage and payment for telehealth services; S2459, the Empower Act HR 4878.
EMPOWER Act
Client: NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES · Firm: WILLIAMS AND JENSEN, PLLC
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Proposals to extend coverage and payment for telehealth services; S2459, the Empower Act HR 4878.
EMPOWER Act
Client: NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES · Firm: WILLIAMS AND JENSEN, PLLC
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Proposals to extend coverage and payment for telehealth services; S2459, the Empower Act HR 4878.
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821). American Relief Act (P.L. 118-158).
Promoting Resilient Supply Chains Act of 2023
Client: EXIGER · Firm: WILLIAMS AND JENSEN, PLLC
S.4375, the Promoting Resilient Supply Chains Act of 2024; H.R.6571, Promoting Resilient Supply Chains Act of 2023
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
Tax Relief for American Families and Workers Act of 2024
Client: BUSINESS ROUNDTABLE · Firm: WILLIAMS AND JENSEN, PLLC
H.R.7024--Tax Relief for American Families and Workers Act of 2024. Issues of interest to the broad business community, including corporate tax rate and international tax rules.
Tax Relief for American Families and Workers Act of 2024
Client: BUSINESS ROUNDTABLE · Firm: WILLIAMS AND JENSEN, PLLC
H.R.7024--Tax Relief for American Families and Workers Act of 2024. Issues of interest to the broad business community, including tax and general matters.
Tax Relief for American Families and Workers Act of 2024
Client: BUSINESS ROUNDTABLE · Firm: WILLIAMS AND JENSEN, PLLC
H.R.7024--Tax Relief for American Families and Workers Act of 2024. Issues of interest to the broad business community, including corporate tax rate and international tax rules.
Tax Relief for American Families and Workers Act of 2024
Client: BUSINESS ROUNDTABLE · Firm: WILLIAMS AND JENSEN, PLLC
H.R.7024--Tax Relief for American Families and Workers Act of 2024. Issues of interest to the broad business community, including corporate tax rate and international tax rules.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: EXIGER · Firm: WILLIAMS AND JENSEN, PLLC
Supply Chain Security issues. S.4638, National Defense Authorization Act for Fiscal Year 2025 and H.R. 8070, the Service Member Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025, related to supply chain illumination and transparency in acquisition waivers.
Competitive Bidding Relief Act of 2023
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821). American Relief Act (P.L. 118-158).
Competitive Bidding Relief Act of 2023
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Competitive Bidding Relief Act of 2023
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Competitive Bidding Relief Act of 2023
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act. American Relief Act (P.L. 118-158).
Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act.
Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act.
Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act
Client: NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES · Firm: WILLIAMS AND JENSEN, PLLC
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Proposals to extend coverage and payment for telehealth services; S2459, the Empower Act HR 4878.
Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act
Client: NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES · Firm: WILLIAMS AND JENSEN, PLLC
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Proposals to extend coverage and payment for telehealth services; S2459, the Empower Act HR 4878.
Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act
Client: NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES · Firm: WILLIAMS AND JENSEN, PLLC
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Proposals to extend coverage and payment for telehealth services; S2459, the Empower Act HR 4878.
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821). American Relief Act (P.L. 118-158).
Promoting Resilient Supply Chains Act of 2024
Client: EXIGER · Firm: WILLIAMS AND JENSEN, PLLC
S.4375, the Promoting Resilient Supply Chains Act of 2024; H.R.6571, Promoting Resilient Supply Chains Act of 2023
National Defense Authorization Act for Fiscal Year 2025
Client: EXIGER · Firm: WILLIAMS AND JENSEN, PLLC
Supply Chain Security issues. S.4638, National Defense Authorization Act for Fiscal Year 2025 and H.R. 8070, the Service Member Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025, related to supply chain illumination and transparency in acquisition waivers.
Animal Drug and Animal Generic Drug User Fee Amendments of 2023
Client: ZOETIS · Firm: WILLIAMS AND JENSEN, PLLC
Animal health , issues impacting medicines and vaccines for animals; ADUFA Reauthorization. (H.R. 1418; S. 1844, H.R. 5860).
Animal Drug and Animal Generic Drug User Fee Amendments of 2023
Client: ZOETIS · Firm: WILLIAMS AND JENSEN, PLLC
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; ADUFA Reauthorization (H.R. 1418, S. 1844, H.R. 5860); Innovative FEED Act (S. 1842, H.R. 6687).
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to oncology and multi-cancer early detection, including diagnostics and screening. H.R. 2407- Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act. S. 2085- Medicare Multi-Cancer Early Detection Screening Coverage Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407.
Issues related to mental health; insurance issues related to Medicare coverage, Medicare Advantage issues; issues related to CMS; issues related to military health TRICARE program, Veterans Health Issues, NDAA; telehealth issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESEARCH SOCIETY ON ALCOHOL (FORMERLY KNOWNS AS RESEARCH SOCIETY ON ALCOHOLISM) via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · 4T
General education to advance federal funding and policies to support continued alcohol research and strategies to address alcohol-related disorders.
Funding for alcohol research and substance use disorders in FY 2024 House and Senate appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.
Matters affecting plasma donation and potential plasma shortages. Issues related to PAHPA.
Matters related to access to and pricing of plasma derived products and matters affecting the Orphan Drug Act and therapies for rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN, INC. via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Policies impacting disease prevention.
Issues related to patent protections.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health.
Tax issues related to the pharmaceutical industry.
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOETIS via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI, U.S. via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158).
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.
Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
NOVO NORDISK INC. via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
SYNEOS HEALTH, INC. via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Clinical trials and research.
Remote clinical trials, biomedical research & development, issues related to diversity in clinical trials.
Business and corporate tax issues, international tax reform; including international minimum tax proposals; issues related to research and development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAYNER via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Medicare coverage issue for non-opioid product.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PFIZER via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Issues related to pharmaceutical manufacturing and development.
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access.
Issues related to pharmaceutical manufacturing and development. Legislative proposals related to WTO TRIPS Waiver.
PHRMA via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Issues related to pharmaceutical manufacturing and development.
Issues related to pharmaceutical development; Policies impacting Medicare Part D; Part B and 340 B programs.
IP Protections related to trade agreements; trade policies impacting pharaceutical development. Legislative proposals related to WTO TRIPS Waiver.
OWENS & MINOR, INC. via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Monitor and track trade actions and developments that could impact PPE; Section 301 tariffs on PPE.
PPE supply chain and COVID-19; Strategic National Stockpile; PPE Manufacturing; Federal initiatives to support domestic manufacturing.
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421). American Relief Act (P.L. 118-158).
MERCK & CO INC via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Tax policy impacting health care and pharmaceutical industry.
Drug pricing proposals. Pharmacy Benefit Manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158).
Drug pricing proposals. Pharmacy Benefit Manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, LLC via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act. American Relief Act (P.L. 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY & COMPANY via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Issues related to pharmaceutical manufacturing and development.
Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
ARGENTUM MEDICAL via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Educate and inform Members about a FDA proposed rule. Reclassification of wound care products and the potential consequences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RIVER REGION PSYCHIATRY ASSOCIATES via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Work to educate Republican and Democrat members on the unique model of RRPA for providing psychiatric care and developing potential care pilot programs in Medicaid and/or CMMI.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
EXIGER via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Supply Chain Security issues. S.4638, National Defense Authorization Act for Fiscal Year 2025 and H.R. 8070, the Service Member Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025, related to supply chain illumination and transparency in acquisition waivers.
Supply Chain Security Issues.
S.4375, the Promoting Resilient Supply Chains Act of 2024; H.R.6571, Promoting Resilient Supply Chains Act of 2023
BUSINESS ROUNDTABLE via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
H.R.7024--Tax Relief for American Families and Workers Act of 2024. Issues of interest to the broad business community, including corporate tax rate and international tax rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOETIS via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SYNEOS HEALTH, INC. via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Remote clinical trials, biomedical research & development, issues related to diversity in clinical trials.
Clinical trials and research.
Business and corporate tax issues, international tax reform; including international minimum tax proposals; issues related to research and development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI, U.S. via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.
RAYNER via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Medicare coverage issue for non-opioid product.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PFIZER via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Tax issues affecting the pharmaceutical industry including international tax. Vaccine excise tax issues and VICP.
Issues related to pharmaceutical manufacturing and development.
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access.
PHRMA via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Public Law 118-47.
IP Protections related to trade agreements; trade policies impacting pharaceutical development. Legislative proposals related to WTO TRIPS Waiver.
OWENS & MINOR, INC. via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
PPE supply chain and COVID-19; Strategic National Stockpile; PPE Manufacturing; Federal initiatives to support domestic manufacturing.
Monitor and track trade actions and developments that could impact PPE; Section 301 tariffs on PPE.
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421).
NOVO NORDISK INC. via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Support for obesity drug coverage and access.
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Monitor general business tax issues.
MERCK & CO INC via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Drug pricing proposals. Pharmacy Benefit Manager reform proposals. Public Law 118-47.
Tax policy impacting health care and pharmaceutical industry.
Drug pricing proposals. Pharmacy Benefit Manager reform proposals. Public Law 118-47.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, LLC via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY & COMPANY via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Issues related to pharmaceutical manufacturing and development.
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
ARGENTUM MEDICAL via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Educate and inform Members about a FDA proposed rule. Reclassification of wound care products and the potential consequences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Issues related to mental health; insurance issues related to Medicare coverage, Medicare Advantage issues; issues related to CMS; issues related to military health TRICARE program, Veterans Health Issues, NDAA; telehealth issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Matters related to access to and pricing of plasma derived products and matters affecting the Orphan Drug Act and therapies for rare diseases.
Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.
Matters affecting plasma donation and potential plasma shortages. Issues related to PAHPA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN, INC. via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Tax issues related to the pharmaceutical industry.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health.
Policies impacting disease prevention.
RESEARCH SOCIETY ON ALCOHOL (FORMERLY KNOWNS AS RESEARCH SOCIETY ON ALCOHOLISM) via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Funding for alcohol research and substance use disorders in FY 2024 House and Senate appropriations.
General education to advance federal funding and policies to support continued alcohol research and strategies to address alcohol-related disorders.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RIVER REGION PSYCHIATRY ASSOCIATES via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Work to educate Republican and Democrat members on the unique model of RRPA for providing psychiatric care and developing potential care pilot programs in Medicaid and/or CMMI.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · 3T
Proposals to extend coverage and payment for telehealth services after the public health emergency.
Issues related to therapy services and telehealth.
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Proposals to extend coverage and payment for telehealth services; S2459, the Empower Act HR 4878.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IRHYTHM TECHNOLOGIES via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · 3T
Issues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to the Medicare Physician Fee Schedule. Issues related to Covid 19.
Issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · 3T
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage program. Telehealth policies. H.R. 3417.
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. Policies impacting U.S. address to the Covid-19 pandemic. Telehealth policies. H.R. 3417.
Tax issues related to health insurance industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIVIOR, INC. via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · 3T
Tax credits and tax issues related to the pharmaceutical industry.
General education on issues related to the Drug Enforcement Agency (DEA), issues related to substance abuse addiction and treatment, including NIH/HHS funding levels, Issues related to access to addiction treatments, including telehealth. Support Act Reauthorization.
Policies impacting access to substance abuse treatment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ZOETIS via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Monitor general business tax issues.
Support for obesity drug coverage and access.
General issues related to patent protections.
SANOFI, U.S. via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.
Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues.
Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
SYNEOS HEALTH, INC. via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Clinical trials and research.
Business and corporate tax issues, international tax reform; including international minimum tax proposals; issues related to research and development.
Remote clinical trials, biomedical research & development, issues related to diversity in clinical trials.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAYNER via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Medicare coverage issue for non-opioid product.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PFIZER via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Issues related to pharmaceutical manufacturing and development. Legislative proposals related to WTO TRIPS Waiver.
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47.
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access.
PHRMA via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Issues related to pharmaceutical manufacturing and development.
IP Protections related to trade agreements; trade policies impacting pharaceutical development. Legislative proposals related to WTO TRIPS Waiver.
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Public Law 118-47.
OWENS & MINOR, INC. via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
FY25 Appropriations
PPE supply chain and COVID-19; Strategic National Stockpile; PPE Manufacturing; Federal initiatives to support domestic manufacturing.
MERCK & CO INC via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Drug pricing proposals. Pharmacy Benefit Manager reform proposals. Public Law 118-47.
Drug pricing proposals. Pharmacy Benefit Manager reform proposals. Public Law 118-47.
Tax policy impacting health care and pharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, LLC via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY & COMPANY via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Issues related to pharmaceutical manufacturing and development.
ARGENTUM MEDICAL via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Educate and inform Members about a FDA proposed rule. Reclassification of wound care products and the potential consequences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BUSINESS ROUNDTABLE via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
H.R.7024--Tax Relief for American Families and Workers Act of 2024. Issues of interest to the broad business community, including corporate tax rate and international tax rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. Policies impacting U.S. address to the Covid-19 pandemic. Telehealth policies. H.R. 3417.
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage program. Telehealth policies. H.R. 3417.
Tax issues related to health insurance industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RIVER REGION PSYCHIATRY ASSOCIATES via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Work to educate Republican and Democrat members on the unique model of RRPA for providing psychiatric care and developing potential care pilot programs in Medicaid and/or CMMI.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Issues related to mental health; insurance issues related to Medicare coverage, Medicare Advantage issues; issues related to CMS; issues related to military health TRICARE program, Veterans Health Issues, NDAA; telehealth issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Proposals to extend coverage and payment for telehealth services after the public health emergency.
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Proposals to extend coverage and payment for telehealth services; S2459, the Empower Act HR 4878.
Issues related to therapy services and telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INDIVIOR, INC. via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
General education on issues related to the Drug Enforcement Agency (DEA), issues related to substance abuse addiction and treatment, including NIH/HHS funding levels, Issues related to access to addiction treatments, including telehealth. Support Act Reauthorization.
Policies impacting access to substance abuse treatment.
Tax credits and tax issues related to the pharmaceutical industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
IRHYTHM TECHNOLOGIES via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Issues related to artificial intelligence.
Issues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to the Medicare Physician Fee Schedule. Issues related to Covid 19.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Matters related to access to and pricing of plasma derived products and matters affecting the Orphan Drug Act and therapies for rare diseases.
Matters affecting plasma donation and potential plasma shortages. Issues related to PAHPA.
Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN, INC. via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · Q2
Policies impacting disease prevention.
Issues related to patent protections.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health.
RECORA via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · 2T
Issues related to Medicare coverage of telehealth and health provider supervision flexibilities. Medicare coverage of virtual and in-home cardiac rehabilitation services, including H.R. 1406--Sustainable Cardiopulmonary Rehabilitation Services in the Home Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARGENTUM MEDICAL via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · RR
Educate and inform Members about a FDA proposed rule. Reclassification of wound care products and the potential consequences.
RIVER REGION PSYCHIATRY ASSOCIATES via WILLIAMS AND JENSEN, PLLC
2024 · second_quarter · RR
Work to educate Republican and Democrat Members on the unique model of RRPA for providing psychiatric care and developing potential care pilot programs in Medicaid and/or CMMI.
BUSINESS ROUNDTABLE via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
H.R.7024--Tax Relief for American Families and Workers Act of 2024. Issues of interest to the broad business community, including tax and general matters.
Issues relating to FY 24 Appropriations/government funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOETIS via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Monitor general business tax issues.
SANOFI, U.S. via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals.
SYNEOS HEALTH, INC. via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Business and corporate tax issues, international tax reform; including international minimum tax proposals; issues related to research and development.
Remote clinical trials, biomedical research & development, issues related to diversity in clinical trials.
Clinical trials and research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAYNER via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Medicare coverage issue for non-opioid product.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PFIZER via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Issues related to pharmaceutical manufacturing and development.
Issues related to pharmaceutical manufacturing and development. Legislative proposals related to WTO TRIPS Waiver.
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47.
PHRMA via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Public Law 118-47.
Issues related to pharmaceutical manufacturing and development.
IP Protections related to trade agreements; trade policies impacting pharaceutical development. Legislative proposals related to WTO TRIPS Waiver.
OWENS & MINOR, INC. via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421).
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
PPE supply chain and COVID-19; Strategic National Stockpile; PPE Manufacturing; Federal initiatives to support domestic manufacturing.
MERCK & CO INC via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Drug pricing proposals. Pharmacy Benefit Manager reform proposals. Public Law 118-47.
Drug pricing proposals. Pharmacy Benefit Manager reform proposals. Public Law 118-47.
Tax policy impacting health care and pharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DR. EMIL KAKKIS via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
FDA regulatory review and approval issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, LLC via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY & COMPANY via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.
Issues related to pharmaceutical manufacturing and development.
Issues related to pharmaceutical manufacturing and development.
ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. Policies impacting U.S. address to the Covid-19 pandemic. Telehealth policies.
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage program. Telehealth policies.
Tax issues related to health insurance industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Issues related to mental health; insurance issues related to Medicare coverage, Medicare Advantage issues; issues related to CMS; issues related to military health TRICARE program, Veterans Health Issues, NDAA; telehealth issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Proposals to extend coverage and payment for telehealth services after the public health emergency.
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Proposals to extend coverage and payment for telehealth services; S2459, the Empower Act HR 4878.
Issues related to therapy services and telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INDIVIOR, INC. via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
General education on issues related to the Drug Enforcement Agency (DEA), issues related to substance abuse addiction and treatment, including NIH/HHS funding levels, Issues related to access to addiction treatments, including telehealth. Support Act Reauthorization.
Tax credits and tax issues related to the pharmaceutical industry.
Policies impacting access to substance abuse treatment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
IRHYTHM TECHNOLOGIES via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Issues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to the Medicare Physician Fee Schedule. Issues related to Covid 19.
Issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Matters related to access to and pricing of plasma derived products and matters affecting the Orphan Drug Act and therapies for rare diseases.
Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.
Matters affecting plasma donation and potential plasma shortages. Issues related to PAHPA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN, INC. via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health.
Tax issues related to the pharmaceutical industry.
RECORA via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · Q1
Issues related to Medicare coverage of telehealth and health provider supervision flexibilities. Medicare coverage of virtual and in-home cardiac rehabilitation services, including H.R. 1406--Sustainable Cardiopulmonary Rehabilitation Services in the Home Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOLVD HEALTH via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · RR
Promote and educate Congress Administration and Health Organizations on the value of AvertD and other SOLVD products
Promote and educate Congress Administration and Health Organizations on the value of AvertD and other SOLVD products
Promote and educate Congress Administration and Health Organizations on the value of AvertD and other SOLVD products
WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · RR
Issues related to mental health; insurance issues related to Medicare coverage, Medicare Advantage issues; issues related to CMS; issues related to military health TRICARE program, Veterans Health Issues, NDAA; telehealth issues.
Issues related to mental health; insurance issues related to Medicare coverage, Medicare Advantage issues; issues related to CMS; issues related to military health TRICARE program, Veterans Health Issues, NDAA; telehealth issues.
RECORA via WILLIAMS AND JENSEN, PLLC
2024 · first_quarter · RR
Provide government affairs services and support for Recora's legislative priorities, including H.R. 1406, the Sustainable Cardiopulmonary Rehabilitation Services in the Home Act.
Provide government affairs services and support for Recora's legislative priorities, including H.R. 1406, the Sustainable Cardiopulmonary Rehabilitation Services in the Home Act.
NOVO NORDISK INC. via WILLIAMS AND JENSEN, PLLC
2023 · fourth_quarter · Q4
General issues related to patent protections.
Support for obesity drug coverage and access.
Monitor general business tax issues.
ZOETIS via WILLIAMS AND JENSEN, PLLC
2023 · fourth_quarter · Q4
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; ADUFA Reauthorization (H.R. 1418, S. 1844, H.R. 5860); Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals; ADUFA Reauthorization. (H.R. 1418; S. 1844, H.R. 5860).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SYNEOS HEALTH, INC. via WILLIAMS AND JENSEN, PLLC
2023 · fourth_quarter · Q4
Clinical trials and research.
Business and corporate tax issues, international tax reform; including international minimum tax proposals; issues related to research and development.
Remote clinical trials, biomedical research & development, issues related to diversity in clinical trials, real world evidence, pandemic preparedness reauthorization.
SANOFI, U.S. via WILLIAMS AND JENSEN, PLLC
2023 · fourth_quarter · Q4
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals.
Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues.
RAYNER via WILLIAMS AND JENSEN, PLLC
2023 · fourth_quarter · Q4
Medicare coverage issue for non-opioid product.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PHRMA via WILLIAMS AND JENSEN, PLLC
2023 · fourth_quarter · Q4
IP Protections related to trade agreements; trade policies impacting pharaceutical development. Legislative proposals related to WTO TRIPS Waiver.
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals.
PFIZER via WILLIAMS AND JENSEN, PLLC
2023 · fourth_quarter · Q4
Issues related to pharmaceutical manufacturing and development.
Tax issues affecting the pharmaceutical industry including international tax. Vaccine excise tax issues and VICP.
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution.
OWENS & MINOR, INC. via WILLIAMS AND JENSEN, PLLC
2023 · fourth_quarter · Q4
Medicare rate for non-CBA/non-rural DME suppliers; PHE Extension. Issues related to Medicare DME payment rates in competitive bidding and non-competitive bidding areas; Issues related to home oxygen medical necessity documentation; DRA of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294).
Pandemic Preparedness Reauthorization - Strategic National Stockpile PPE Manufacturing; Support for domestic sourcing of medical/surgical Personal Protective Equipment ("PPE"). Issues relating to FDA regulation of medical devices.
Monitor and track trade actions and developments that could impact PPE; Section 301 tariffs on PPE.
MERCK & CO INC via WILLIAMS AND JENSEN, PLLC
2023 · fourth_quarter · Q4
Drug pricing proposals. Pharmacy Benefit Manager reform proposals.
Tax policy impacting health care and pharmaceutical industry.
Drug pricing proposals. Pharmacy Benefit Manager reform proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, LLC via WILLIAMS AND JENSEN, PLLC
2023 · fourth_quarter · Q4
H.R. 2407/S.2085, The Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY & COMPANY via WILLIAMS AND JENSEN, PLLC
2023 · fourth_quarter · Q4
Accelerated approval pathway; support for Alzheimers diagnostics; FY 2024 Appropriations.
Issues related to pharmaceutical manufacturing and development.
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158).
Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Support for obesity drug coverage and access.
General issues related to patent protections.
Monitor general business tax issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158).
Tax issues affecting the pharmaceutical industry including international tax. Vaccine excise tax issues and VICP.
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158).
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821). American Relief Act (P.L. 118-158).
FY25 Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmaceutical manufacturing and development.
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
International and domestic tax issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Supply Chain Resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47.
Issues related to pharmaceutical manufacturing and development. Legislative proposals related to WTO TRIPS Waiver.
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmaceutical manufacturing and development.
Issues related to pharmaceutical development; Policies impacting Medicare Part D; Part B and 340 B programs.
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Public Law 118-47.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FY25 Appropriations
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
General issues related to patent protections.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmaceutical manufacturing and development.
International and domestic tax issues.
Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to patent protections.
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47.
Issues related to pharmaceutical manufacturing and development.
Tax issues affecting the pharmaceutical industry including international tax. Vaccine excise tax issues and VICP.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmaceutical development; Policies impacting Medicare Part D; Part B and 340 B programs.
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Public Law 118-47.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitor and track trade actions and developments that could impact PPE; Section 301 tariffs on PPE.
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmaceutical manufacturing and development.
International and domestic tax issues.
Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Tax issues related to the pharmaceutical industry.
General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to patent protections.
Support for obesity drug coverage and access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Tax issues affecting the pharmaceutical industry including international tax. Vaccine excise tax issues and VICP.
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47.
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmaceutical development; Policies impacting Medicare Part D; Part B and 340 B programs.
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Public Law 118-47.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitor and track trade actions and developments that could impact PPE; Section 301 tariffs on PPE.
FY24 Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
International and domestic tax issues.
General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policies impacting disease prevention.
Issues related to patent protections.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Promote and educate Congress Administration and Health Organizations on the value of AvertD and other SOLVD products
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407.
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Remote clinical trials, biomedical research & development, issues related to diversity in clinical trials.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. Policies impacting U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals.
Issues related to pharmaceutical development; Policies impacting Medicare Part D; Part B and 340 B programs.
Issues related to pharmaceutical manufacturing and development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals.
Issues related to pharmaceutical manufacturing and development. Legislative proposals related to WTO TRIPS Waiver.
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PPE supply chain and COVID-19; Strategic National Stockpile; PPE Manufacturing; Federal initiatives to support domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407.
International and domestic tax issues.
Issues related to pharmaceutical manufacturing and development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE